Literature DB >> 6779980

Prognosis in giant-cell arteritis.

E Graham, A Holland, A Avery, R W Russell.   

Abstract

In a study to assess the natural history of giant-cell arteritis, 90 patients with proved disease were followed up from the time of diagnosis. Early mortality was low and most commonly due to vertebral arteritis, but cerebral infarction did not appear to be a late complication. High maintenance dose steroids and visual loss were associated significantly with a shortened life span (p=0.0003 and p=0.0024). One-third of the patients developed chronic relapsing disease, but serious late complications were not encountered. After the initial attack has been controlled steroid dosage should be reduced to the minimum needed to alleviate symptoms.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6779980      PMCID: PMC1504093          DOI: 10.1136/bmj.282.6260.269

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  8 in total

1.  Ocular palsy in temporal arteritis. I.

Authors:  C M FISHER
Journal:  Minn Med       Date:  1959-09

2.  The visual changes in temporal (giant-cell) arteritis. Report of a case with autopsy findings.

Authors:  M R CROMPTON
Journal:  Brain       Date:  1959-09       Impact factor: 13.501

3.  Sudden blindness in cranial arteritis.

Authors:  G PARSONS-SMITH
Journal:  Br J Ophthalmol       Date:  1959-04       Impact factor: 4.638

4.  Giant-Cell or Temporal Arteritis: a Review.

Authors:  C V Harrison
Journal:  J Clin Pathol       Date:  1948-08       Impact factor: 3.411

5.  Ophthalmoplegia in cranial arteritis.

Authors:  M E Barricks; D B Traviesa; J S Glaser; I S Levy
Journal:  Brain       Date:  1977-06       Impact factor: 13.501

6.  Computing man years at risk.

Authors:  I D Hill
Journal:  Br J Prev Soc Med       Date:  1972-05

7.  Visual system involvement in giant cell (temporal) arteritis.

Authors:  F M Wang; P Henkind
Journal:  Surv Ophthalmol       Date:  1979 Jan-Feb       Impact factor: 6.048

8.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

  8 in total
  32 in total

1.  Giant cell arteritis.

Authors:  L G Clearkin
Journal:  BMJ       Date:  1992-08-29

Review 2.  Stopping steroids in polymyalgia rheumatica and giant cell arteritis.

Authors:  V Kyle; B L Hazelman
Journal:  BMJ       Date:  1990-02-10

3.  Plasma viscosity or erythrocyte sedimentation rate in the diagnosis of giant cell arteritis?

Authors:  G P Brittain; G G McIlwaine; J A Bell; J M Gibson
Journal:  Br J Ophthalmol       Date:  1991-11       Impact factor: 4.638

4.  Treatable blindness in temporal arteritis.

Authors:  L Clearkin
Journal:  Br J Ophthalmol       Date:  1992-01       Impact factor: 4.638

5.  Internuclear ophthalmoplegia in giant-cell arteritis.

Authors:  P Trend; E Graham
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-06       Impact factor: 10.154

6.  Treatment of polymyalgia rheumatica and giant cell arteritis.

Authors:  M T Watts; M E Nelson; I G Rennie
Journal:  Ann Rheum Dis       Date:  1990-07       Impact factor: 19.103

7.  Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

8.  Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

9.  Giant cell arteritis: A rare cause of posterior vasculitis.

Authors:  Marilita M Moschos; Yan Guex-Crosier
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 10.  Steroid-sparing medications in temporal arteritis--report of three cases and review of 174 reported patients.

Authors:  G Nesher; M Sonnenblick
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.